Ausgabe 2/2012
Inhalt (27 Artikel)
Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta-analysis
Shichao Li, Xinhua Yang, Yi Zhang, Linjun Fan, Fan Zhang, Li Chen, Yan Zhou, Xianchun Chen, Jun Jiang
Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis
Fausto Petrelli, Karen Borgonovo, Mary Cabiddu, Veronica Lonati, Sandro Barni
Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis
Aaron M. Drucker, Shenhong Wu, Chau T. Dang, Mario E. Lacouture
Systemic therapy options in BRCA mutation-associated breast cancer
Soley Bayraktar, Stefan Glück
Physical activity and mammographic breast density: a systematic review
Lusine Yaghjyan, Graham A. Colditz, Kathleen Wolin
The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer
Kristin Jonsdottir, Hui Zhang, Darshni Jhagroe, Ivar Skaland, Aida Slewa, Benny Björkblom, Eleanor T. Coffey, Einar Gudlaugsson, Rune Smaaland, Emiel A. M. Janssen, Jan P. A. Baak
Beyond radiation therapy: photodynamic therapy maintains structural integrity of irradiated healthy and metastatically involved vertebrae in a pre-clinical in vivo model
Victor C. K. Lo, Margarete K. Akens, Sara Moore, Albert J. M. Yee, Brian C. Wilson, Cari M. Whyne
Loss of Dicer expression is associated with breast cancer progression and recurrence
Sarkawt M. Khoshnaw, Emad A. Rakha, Tarek M. Abdel-Fatah, Christopher C. Nolan, Zsolt Hodi, Douglas R. Macmillan, Ian O. Ellis, Andrew R. Green
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures
Peter Kabos, Jessica Finlay-Schultz, Chunling Li, Enos Kline, Christina Finlayson, Joshua Wisell, Christopher A. Manuel, Susan M. Edgerton, J. Chuck Harrell, Anthony Elias, Carol A. Sartorius
Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells
Warren Fiskus, Stacey L. Hembruff, Rekha Rao, Priyanka Sharma, Ramesh Balusu, Sreedhar Venkannagari, Jacqueline E. Smith, Karissa Peth, Stephen C. Peiper, Kapil N. Bhalla
Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion
Tao Zhang, Jingjie Li, Yanmin Dong, Dong Zhai, Li Lai, Fujun Dai, Huayun Deng, Yihua Chen, Mingyao Liu, Zhengfang Yi
Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients
Fangfang Liu, Yaqing Li, Meijing Ren, Xinmin Zhang, Xiaojing Guo, Ronggang Lang, Feng Gu, Li Fu
Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression
Ben A. Hall, Tae Yeon Kim, Maxwell N. Skor, Suzanne D. Conzen
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer
Johanna Tuomela, Jouko Sandholm, Peeter Karihtala, Joanna Ilvesaro, Katri S. Vuopala, Joonas H. Kauppila, Saila Kauppila, Dongquan Chen, Christine Pressey, Pirkko Härkönen, Kevin W. Harris, David Graves, Päivi K. Auvinen, Ylermi Soini, Arja Jukkola-Vuorinen, Katri S. Selander
Transcriptional activation of breast cancer-associated gene 2 by estrogen receptor
Fathima R. Kona, Karri Stark, Luke Bisoski, Daniela Buac, Qiuzhi Cui, Q. Ping Dou
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
Anneleen Daemen, Denise M. Wolf, James E. Korkola, Obi L. Griffith, Jessica R. Frankum, Rachel Brough, Lakshmi R. Jakkula, Nicholas J. Wang, Rachael Natrajan, Jorge S. Reis-Filho, Christopher J. Lord, Alan Ashworth, Paul T. Spellman, Joe W. Gray, Laura J. van’t Veer
MMP-9 increases HER2/neu expression and alters apoptosis levels in human mammary epithelial cells (HMEC)
Matilda Fatunmbi, Justin Shelton, Susan M. Aronica
TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy
Jiayu Wang, Binghe Xu, Peng Yuan, Pin Zhang, Qing Li, Fei Ma, Ying Fan
Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer
Steven D. Heys, Keith N. Stewart, Emma J. McKenzie, Iain D. Miller, Simon Y. C. Wong, Grant Sellar, Andrew J. Rees
Regular screening mammography before the diagnosis of breast cancer reduces black:white breast cancer differences and modifies negative biological prognostic factors
Paula Grabler, Danielle Dupuy, Jennifer Rai, Sean Bernstein, David Ansell
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women
A. J. Agboola, A. A. Musa, N. Wanangwa, T. Abdel-Fatah, C. C. Nolan, B. A. Ayoade, T. Y. Oyebadejo, A. A. Banjo, A. M. Deji-Agboola, E. A. Rakha, A. R. Green, I. O. Ellis
Mammographic density and breast cancer risk in White and African American Women
Hilda Razzaghi, Melissa A. Troester, Gretchen L. Gierach, Andrew F. Olshan, Bonnie C. Yankaskas, Robert C. Millikan
Preventing weight gain during adjuvant chemotherapy for breast cancer: a dietary intervention study
A. Villarini, P. Pasanisi, M. Raimondi, G. Gargano, E. Bruno, D. Morelli, A. Evangelista, P. Curtosi, F. Berrino
Patient awareness and knowledge of breast cancer-related lymphedema in a large, integrated health care delivery system
Marilyn L. Kwan, Ling Shen, Julie R. Munneke, Emily K. Tam, Paula N. Partee, Mary André, Susan E. Kutner, Carol P. Somkin, Lynn M. Ackerson, Saskia R. J. Thiadens
Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case–control study
Isabelle Le Ray, Sophie Dell’Aniello, Franck Bonnetain, Laurent Azoulay, Samy Suissa
Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women’s Health Initiative observational study
Christopher I. Li, Justin E. Mirus, Yuzheng Zhang, Arturo B. Ramirez, Jon J. Ladd, Ross L. Prentice, Martin W. McIntosh, Samir M. Hanash, Paul D. Lampe
Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer
Y. Delpech, Y. Wu, K. R. Hess, L. Hsu, M. Ayers, R. Natowicz, C. Coutant, R. Rouzier, E. Barranger, G. N. Hortobagyi, D. Mauro, L. Pusztai